Azithromycin 500mg Inj, 1 Vial
Overview
What is this medicine?
How to Use This Medicine
For storage and disposal, consult with your doctor, nurse, or pharmacist to determine the best approach if you need to keep this medication at home.
If you miss a dose, contact your doctor immediately to receive guidance on the appropriate course of action.
Lifestyle & Tips
- Report any unusual or severe side effects to your healthcare provider immediately.
- Do not stop the medication early, even if symptoms improve, unless advised by your doctor.
- Stay hydrated, especially if experiencing diarrhea.
Available Forms & Alternatives
Available Strengths:
- Azithromycin 500mg Inj, 1 Vial
- Azithromycin 1gm Pak Powder
- Azithromycin 600mg Tablets
- Azithromycin 200mg/5ml Susp 15ml
- Azithromycin 200mg/5ml Susp 30ml
- Azithromycin 200mg/5ml Susp 22.5ml
- Azithromycin 100mg/5ml Susp 15ml
- Azithromycin 500mg Sdv Inj, 1 Vial
- Azithromycin 250mg Tablets 6-Pak
- Azithromycin 600mg Tablets
- Azithromycin 500mg Tablets Tri-Pack
- Azithromycin 250mg Tablets
- Azithromycin 500mg Tablets
- Azithromycin 600mg Tablets
Dosing & Administration
Adult Dosing
Condition-Specific Dosing:
Pediatric Dosing
Dose Adjustments
Renal Impairment:
Hepatic Impairment:
Pharmacology
Mechanism of Action
Pharmacokinetics
Absorption:
Distribution:
Elimination:
Pharmacodynamics
Safety & Warnings
Side Effects
Seek Immediate Medical Attention If You Experience:
- Severe or watery diarrhea (especially if bloody or prolonged)
- Yellowing of the skin or eyes (jaundice)
- Dark urine or pale stools
- Severe stomach pain
- Unusual bleeding or bruising
- Fast, pounding, or irregular heartbeat
- Dizziness or fainting spells
- Severe skin rash, blistering, or peeling skin
- Swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing (signs of severe allergic reaction)
Before Using This Medicine
Precautions & Cautions
Overdose Information
Overdose Symptoms:
- Severe nausea
- Vomiting
- Diarrhea
- Reversible hearing loss
What to Do:
In case of suspected overdose, seek immediate medical attention or call a poison control center. In the US, call 1-800-222-1222. Management is supportive and symptomatic.
Drug Interactions
Contraindicated Interactions
- Pimozide (risk of QT prolongation)
Major Interactions
- Warfarin (increased INR, bleeding risk)
- Nelfinavir (increased azithromycin levels)
- Ergot derivatives (e.g., ergotamine, dihydroergotamine - risk of ergotism)
- QT-prolonging drugs (e.g., Class IA and III antiarrhythmics, cisapride, terfenadine, some antipsychotics, tricyclic antidepressants, fluoroquinolones - increased risk of Torsades de Pointes)
Moderate Interactions
- Cyclosporine (increased cyclosporine levels)
- Digoxin (increased digoxin levels)
- Atorvastatin (rare reports of rhabdomyolysis, monitor for muscle pain)
- Colchicine (increased colchicine exposure)
Minor Interactions
- Antacids (oral only, not relevant for IV)
Monitoring
Baseline Monitoring
Rationale: To assess baseline hepatic function, especially in patients with pre-existing liver disease.
Timing: Prior to initiation of therapy if hepatic impairment is suspected or known.
Rationale: To assess baseline QT interval, especially in patients with known QT prolongation, uncorrected hypokalemia/hypomagnesemia, bradycardia, or concurrent use of other QT-prolonging drugs.
Timing: Prior to initiation of therapy if risk factors for QT prolongation are present.
Routine Monitoring
Frequency: Daily during acute treatment, then as clinically indicated.
Target: Resolution of signs and symptoms of infection.
Action Threshold: Lack of improvement or worsening symptoms may indicate treatment failure or resistant organism.
Frequency: As clinically indicated, especially with prolonged therapy or signs/symptoms of hepatic dysfunction (e.g., jaundice, dark urine, fatigue).
Target: Within normal limits or stable.
Action Threshold: Significant elevation (e.g., >3x ULN) may warrant discontinuation.
Frequency: Periodically, if risk factors for QT prolongation persist or new risk factors emerge.
Target: QTc < 450 ms (men), < 470 ms (women).
Action Threshold: QTc prolongation > 500 ms or increase of > 60 ms from baseline may warrant discontinuation or closer monitoring.
Frequency: More frequently during and after azithromycin therapy.
Target: Individualized therapeutic range.
Action Threshold: INR outside target range requires dose adjustment of warfarin.
Symptom Monitoring
- Signs of allergic reaction (rash, itching, hives, swelling of face/lips/tongue/throat, difficulty breathing)
- Severe or persistent diarrhea (may indicate Clostridioides difficile-associated diarrhea)
- Signs of hepatotoxicity (yellowing of skin/eyes, dark urine, pale stools, severe stomach pain, unusual fatigue)
- Signs of QT prolongation/arrhythmia (palpitations, dizziness, lightheadedness, fainting, shortness of breath)
- Signs of superinfection (new or worsening fever, new infection symptoms)
- Muscle pain or weakness (if on statins)
Special Patient Groups
Pregnancy
Pregnancy Category B. Studies in animals have not shown harm to the fetus. Adequate and well-controlled studies in pregnant women are lacking. Use during pregnancy only if clearly needed and the potential benefits outweigh the potential risks.
Trimester-Specific Risks:
Lactation
Lactation Risk Category L3 (Moderately Safe). Azithromycin is excreted into breast milk in low concentrations. Potential for infant gastrointestinal upset (diarrhea, vomiting) or alteration of gut flora. Monitor breastfed infant for side effects.
Pediatric Use
Safe and effective for certain indications in children 6 months of age and older. Dosing is weight-based. Safety and effectiveness in pediatric patients under 6 months of age have not been established.
Geriatric Use
No specific dosage adjustment is necessary based on age alone. However, elderly patients may be more susceptible to drug-associated QT interval prolongation. Monitor carefully, especially if co-morbidities or concomitant medications increase this risk.
Clinical Information
Clinical Pearls
- Azithromycin IV should be administered as an intravenous infusion over at least 60 minutes to minimize local reactions at the infusion site.
- Do NOT administer azithromycin IV as a bolus or intramuscular injection.
- Patients should be switched to oral azithromycin therapy as soon as clinically appropriate.
- Azithromycin exhibits a long post-antibiotic effect and high tissue penetration, allowing for once-daily dosing and shorter courses of therapy compared to some other antibiotics.
- Caution is advised in patients with pre-existing QT prolongation, uncorrected hypokalemia/hypomagnesemia, clinically significant bradycardia, or those receiving other drugs known to prolong the QT interval, due to the risk of Torsades de Pointes.
- Monitor for signs of C. difficile-associated diarrhea, which can occur even several months after antibiotic discontinuation.
Alternative Therapies
- Other macrolides (e.g., clarithromycin, erythromycin)
- Tetracyclines (e.g., doxycycline)
- Fluoroquinolones (e.g., levofloxacin, moxifloxacin)
- Beta-lactam antibiotics (e.g., ceftriaxone, amoxicillin/clavulanate)
- Depending on the specific infection and susceptibility patterns.